PDSB (PDS Biotechnology) EPS (Basic) : $-1.17 (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is PDS Biotechnology EPS (Basic)?

PDS Biotechnology's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.29. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.17.

PDS Biotechnology's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.29. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.17.

PDS Biotechnology's EPS without NRI for the three months ended in Sep. 2024 was $-0.29. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -1.17.

During the past 3 years, the average EPS without NRI Growth Rate was -16.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 36.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 30.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, PDS Biotechnology's highest 3-Year average EPS without NRI Growth Rate was 70.10% per year. The lowest was -78.60% per year. And the median was 30.75% per year.

PDS Biotechnology EPS (Basic) Historical Data

The historical data trend for PDS Biotechnology's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology EPS (Basic) Chart

PDS Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-1.44

-0.89

-0.66

-1.43

-1.39

PDS Biotechnology Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-0.35	-0.35	-0.30	-0.23	-0.29

PDS Biotechnology EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

PDS Biotechnology's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-42.942	-	0)	/	30.952
	=	-1.39

PDS Biotechnology's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-10.727	-	0)	/	36.807
	=	-0.29

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.17

PDS Biotechnology (NAS:PDSB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

PDS Biotechnology EPS (Basic) Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

PDS Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (NAS:PDSB) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

EU6:Germany

Address

303A College Road, East Princeton, NJ, USA, 08540

Website

https://www.pdsbiotech.com

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Executives

Spencer D. Brown	officer: Senior VP, General Counsel	25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932
Matthew C Hill	officer: Chief Financial Officer	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Delyle W Bloomquist	director, 10 percent owner	RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207
Voorhees Seth Van	officer: Chief Financial Officer	12 HARVEY DRIVE, SHORT HILLS NJ 07078
Kamil Ali-jackson	director	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Stephen C. Glover	director	108 DOCKSIDE CIRCLE, WESTON FL 33327
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Michael N. King	officer: Interim Chief Financial Office	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Ilian Iliev	director	303 A COLLEGE ROAD EAST, PRINCETON NJ 08540
Janetta Trochimiuk	officer: Principal Accounting Officer	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Richard Sykes	director	C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932
Frank Bedu-addo	director, 10 percent owner, officer: President/CEO	300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922
Lauren Wood	officer: Chief Medical Officer	300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922
Gregory Conn	officer: Chief Scientific Officer	300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922